Beta-lactam derivatives for the treatment of diseases
US12162862B2 · kind B2 · utility
0Cited by
4References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2023 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Aug 23, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.